A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of VGA039 Following Intravenous or Subcutaneous Administration of Single Ascending Doses in Healthy Adults and Adult Patients with von Willebrand Disease

Disease Sites:

Not Available

Staging:

Phase I

Age Group:

Adults

Therapies:

Not Available

Drugs:

Not Available

Principal Investigator(s):

Wheeler, Allison

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

10-13-2023

Trial Type:

Treatment

Protocol ID:

NCBH2304-VEGA

National Clinical Trial ID:

NCT05776069

View Internal Documents

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available